Efgartigimod for the Treatment of Guillain-Barré Syndrome

Summary

The goal of this clinical trial is to evaluating the efficacy and safety of efgartigimod in the treatment of Guillain-Barré Syndrome and exploring the immunological mechanisms of efgartigimod therapy in Guillain-Barré Syndrome. The main questions it aims to answer are: Will efgartigimod improve the symptoms of participants? What medical problems do participants have when using efgartigimod? Participants will: On day 1 and day 5 of the treatment period, drug A was administered intravenously. Keep a diary of their symptoms

Timeline

Start

2025-04-13

Primary completion

2026-06-30

Completion

2026-12-31

Drugs

Indications